CRESCENT BIOPHARMA, INC. (CBIO)

Pharmaceutical Preparations · market cap $556M · as of 2026-07-07

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-05 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Crescent Biopharma (CBIO) is a clinical-stage pharmaceutical company with 41 employees and a ~$471M market cap, built around a single disclosed asset: CR-001, currently in Phase 2 for locally advanced/metastatic solid tumors. The mechanism of action for CR-001 is not publicly disclosed in available data, and no recent clinical readouts have been reported.

The catalyst path

2026-11-05 (est.)Earningsimp 5/10

Pipeline

Asset	Phase	Indication
CR-001	Phase 2	Locally Advanced / Metastatic Solid Tumors

Price & technical context

3-month

-15.3%

6-month

-26.0%

12-month

+20.7%

52-wk range

$8.94–$26.98

vs 50-day MA

-14.7%

vs 200-day MA

-8.7%

Realized vol

80.3%

Max drawdown

-81.8%

Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for CBIO (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.